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Se´zary syndrome (SS), an aggressive form of erythrodermic pruritic cutaneous T cell lymphoma (CTCL), from an immunological
perspective characterized by increasedTh2 cytokine levels, elevated serum IgE and impaired cellular immunity. Not only the clinical
appearance but also the hallmark immunological characteristics of SS often share striking similarities with acute flares of atopic
dermatitis (AD), a common benign chronic inflammatory skin disease. Given the overlap of several immunological features, the
application of similar or even identical therapeutic approaches in certain stages of both diseases may come into consideration. The
aim of this review is to compare currently accepted immunological aspects and possible therapeutic targets in AD and SS.
1. Introduction
Se´zary syndrome (SS) is a rare erythrodermic and leukemic
variant of cutaneous T cell lymphomas (CTCL) that belongs
to the heterogeneous group of extranodal non-Hodgkin’s
lymphomas (NHL) arising from the malignant proliferation
of skin-homing T cells [1, 2]. SS together with mycosis
fungoides (MF) are the most common forms of CTCL
accounting for around 65% of cases whereas SS represent
around 3% of all CTCL [3]. CTCL are assumed to have amale
predominance and the median age at onset of the disease is
between the fifth and sixth decade [4, 5].
The behaviour of the SS is aggressive with a median
survival of 1–5 years [3, 6, 7]. SS and erythrodermic MF
(E-MF), which is considered to be an advanced form of
MF with absent or minimal blood involvement, may be
referred to as erythrodermic CTCL (E-CTCL) [3, 8]. If blood
involvement is present, the term leukemic CTCL (L-CTCL)
is used and therefore it is applicable to every case of SS
[1, 2]. Besides due to the lack of clear diagnostic markers the
differential diagnosis of various erythrodermic skin diseases
is still challenging [9]. Atopic dermatitis is a common chronic
inflammatory skin disease with a lifetime prevalence of 15–
20% in developed countries [10]. The majority of patients
show an onset in early childhood and a remission until ado-
lescence. However, recent prevalence estimates in adults of up
to 10% indicate that the rate of persistent and/or adult-onset
disease is higher than previously assumed [11, 12]. AD is an
important differential diagnosis of SS in adults with erythro-
dermic dermatitis [10]. Although in majority of cases there
are characteristics such as typical predilection sites for AD
and palmoplantar hyperkeratosis for SS that allow clinically
distinguishing between AD and E-CTCL, in some excep-
tional cases of erythroderma especially among the elderly
population initially it might be a clinical challenge to define
the diagnosis. The comparable clinical features are further
reflected by some overlapping immunological peculiarities,
in particular an epidermal barrier deficiency, and a cutaneous
infiltration by CD4+ T helper cells expressing the skin-
homing receptor cutaneous lymphocyte-associated antigen
(CLA) and chemokine receptor 4 (CCR4). Interestingly, both
AD and SS show increased production ofTh2 cytokines such
as interleukin 4 (IL-4), interleukin 5 (IL-5), and interleukin
13 (IL-13) as well as CCR4-binding chemokines that is
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Figure 1: Clinical appearance of patient with Se´zary syndrome (a) and atopic dermatitis (b).
characteristic also of the acute phase of AD [13–15]. As a
consequence of the epidermal barrier deficiency and the
diminished Th1 and Th17 cell immunity, the skin of AD
patients shows a less diverse surface microbiome and an
increased susceptibility towards cutaneous colonization and
infection with Staphylococcus aureus (S. aureus) [10, 15]. The
skin microbiome has not yet been systematically examined
in CTCL, but there are preliminary data indicating increased
S. aureus colonization rates in MF and SS [16]. Both AD
and SS benefit from topical barrier restoring and rather
unspecific topical or systemic immunosuppressive treatment,
although SS often shows slower and/or weaker responses
[10, 17]. As insights into the precise molecular mechanisms
and key immunological networks driving inflammation grow,
summarizing the knowledge about immune responses in
these Th2 cell-dominated diseases may potentially allow
drawing conclusions about different markers and therapeutic
targets in both of the diseases. The aim of this review is to
compare the immunological aspects and therapeutic targets
in AD and CTCL.
2. Clinical Characteristics of E-CTCL
SS is defined by a typical clinical triad consisting of erythro-
derma, peripheral lymphadenopathy, and peripheral blood
involvement. Although in the majority of SS cases rapid
onset of the clinical manifestations can be observed, in some
patients a long medical history including disabling pruritus
as well as nonspecific dermatitis is present. Cutaneous man-
ifestations in E-CTCL comprise a broad clinical spectrum
varying from mild erythema to generalized exfoliative ery-
throderma complicated by electrolyte dysregulation and high
output cardiac failure due to the extensively dilated skin ves-
sels [18, 19] (Figure 1(a)). Erythroderma is often accompanied
by severe pruritus. Additionally, the patientsmaypresentwith
palmoplantar keratoderma and alopecia and nail changes
varying from discoloration to subungual hyperkeratosis and
ocular involvement, most frequently eyelid ectropion [20–
22]. Elderly patients with erythrodermic eczematous pruritic
skin may be a great clinical challenge for physicians with
regard to differential diagnosis. Some case reports have
described SS arising in patients with a long history of AD [23–
26]. However, a study showed no significant difference in the
prevalence of atopy in SS compared to MF and the general
population [23].
To confirm the definite diagnosis in E-CTCL, clin-
icopathological correlation often including multiple skin
biopsies with histopathological and immunohistochemical
investigations and inmost cases staging examinations (blood,
lymph node, and other organs) are necessary [9, 27–29].
3. Clinical Characteristics of AD
The most characteristic features of AD are intense itch and
recurrent eczematous skin lesions, which typically show an
age-related morphology and distribution. Infants most often
present with eczematous skin lesions on the cheeks and the
scalp while in childhood predilection sites are the flexures,
neck, and dorsal aspects of the limbs (Figure 1(b)). Starting
with adolescence flexural areas, head and neck, shoulders,
and hands are predominantly affected [30, 31]. The majority
of patients display generalized skin dryness and a personal
or familial history of atopy. Other associated features are
a hyperlinearity of the palms and soles, Dennie-Morgan
infraorbital folds, and Hertoghe’s sign [10]. In general, AD
shows a wide spectrum of clinical features and trajectories,
in particular in adulthood, where the disease often presents
as eczematous erythroderma and appears to show a male
predominance [31, 32]. Adult-onset AD often shows an
untypical distribution and morphology of lesions and is not
well captured by classical diagnostic criteria and appears to be
less closely associated with atopy as compared to early-onset
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Figure 2:Th2prevailing immune response in Se´zary syndrome (SS)/erythrodermicMF (E-MF) and atopic dermatitis (AD). (a) SS/E-MFwith
malignant T cells circulating in the blood promote an immune response with production ofTh2 phenotypic cytokines.Therefore suppressing
the Th1 immune properties leads to impaired host immune response. (b) In the acute phase of atopic dermatitis naive T helper cells are
primed in Th2 cells under the influence of activated skin resident DC which have the capacity of migrating to skin-draining lymph nodes.
DC: dendritic cell, Eo: eosinophilic granulocyte.
forms, although reliable clinical and epidemiological data are
lacking [10].
4. Immunological Aspects
In both L-CTCL and acute AD there is a predominance of
Th2 immune response [33, 34]. An overview is shown in
Figure 2.The complexity of theT cell compartment is not fully
understood, and the role of T cells in the regulation of chronic
inflammatory processes in skin diseases as well as in cancer
is puzzling and yet to be defined.
The pathophysiological mechanisms underlying both
entities, the one being a benign inflammatory skin disease,
with the other representing a hematological malignancy of
the skin, will be described with a focus to enlighten the
similarities and differences for both conditions.
4.1. Distinct Features of Pathogenesis of SS (L-CTCL) and AD
4.1.1. Malignant T Cells in CTCL. A cross talk between
different cells of the innate immune system, benign bystander
T cells, and malignant T cells is crucial for the immune
responses in CTCL.
In initial MF skin lesions, an increased number of CD8
cytotoxic cells, in addition to FOXP3 regulatory T cells
(Tregs), have been detected, which was attributed to an
antitumor response promoted by dendritic cells [35–38]; on
the contrary, the disease progression of MF was found to
be associated with a remarkable decrease of normal Treg
and cytotoxic T cells [39]. The exact role of Tregs in CTCL
still remains controversial. Malignant T cells which, in some
SS patients, exhibit phenotype characteristics for Tregs may
contribute to the downregulation of the local antitumor
response as well as systemic immunosuppression [37, 39,
40]. Furthermore, it has been suggested that SS might be a
malignancy of FOXP3+ (forkhead box P3) regulatory T cells,
Th2 cells, and Th17, whereas the presence of Th17 in another
study could not be confirmed [33, 41–43].
Several studies of peripheral blood mononuclear cells
have demonstrated increased production of Th2 cytokines
and reduced production of Th1 cytokines in L-CTCL [44,
45]. Gene expression studies confirmed elevation of Th2
associated genes in the PBMC and skin of patients with L-
CTCL [46, 47]. The association of increased IL-4 production
with advanced stage L-CTCL suggests that the source of
excess Th2 cytokines may be the malignant clone itself.
This hypothesis has recently been corroborated by study-
ing the functional bias of malignant T cells in L-CTCL
patients in whom the malignant T cell clone could be
conclusively identified by staining with antibodies against
TCR V 𝛽. Flow cytometrical assessment of the intracellular
cytokine production demonstrated that both the malignant
clone and surprisingly the remaining benignT cells expressed
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high levels of theTh2 cytokines IL-4 and IL-13 and negligible
levels of IFN-𝛾 upon activation [33].
Several recent studies were dedicated to the origin of the
malignant T cells. Interestingly, malignant T cells, isolated
from the skin of SS patients, showed not only CCR7 and
CCR4 but also high expression of L-selectin and CD27, a
phenotype characteristic of centralmemoryT cells [1]. On the
other hand absence of CCR7/L-selectin and CD27 expression
has been shown in T cells from MF lesions, whereas CCR4
and CLA are highly expressed suggesting a phenotype of skin
resident effector memory T cells [1]. These findings led to
the hypothesis that SS is a malignancy arising from central
memory T cells, while MF is a malignancy of skin resident
effector memory T cells, supporting evidence that SS and
MF should be considered as separate lymphomas originating
from distinct functional T cell subsets [1].
In 2004 Ru¨bben et al. proposed the intriguing hypothesis
that CTCL arises from genetically unstable subclones that
undergo a multilineage progress into a stable clone leading to
subsequent proliferation of neoplastic T cell population that
originates MF [48].
In general, progression of the disease correlates with a
decrease of the T cell receptor (TCR) repertoire, paralleled by
a predominance of clonal, malignant CD4+T cell population,
expressing a single TCR clone [49].
4.1.2. T Cells in AD. Regarding immune dysregulation in AD,
it is known that in acute phase of AD a dense infiltrate of
CD4+ cells as well as allergen specific CD4+ and CD8+ T
cells can be found in the affected skin lesions, thus promoting
cutaneous inflammation [50].
During an acute onset of the disease Th2 bias is charac-
teristic whereas along with the chronification an increasing
proportion of the skin is being infiltrated by Th1 cells
accompanied byTh2, Th0, andTh22 cells [13, 51–54].
In AD naive T helper cells are being polarized into Th2
phenotype by activated skin resident dendritic cells that have
migrated to local lymph nodes [52, 55].
ThehallmarkTh2cytokines IL-4 and IL-13 play important
role in the pathogenesis of AD. Following IL-4 dependent
induction of IgG class switch in B-cells, a subsequent eleva-
tion of IgE levels can be frequently observed in AD patients
[56]. Furthermore, IL-4 is important for the functional
phenotype of immigratingDCprecursors and thereby heavily
influences the phenotype of an ongoing immune response
[34].
Thymus and activation regulated chemokine (TARC/
CCL17), a member of theTh2 chemokine family, serum level
has been suggested to be a useful clinical biomarker for AD
treatment and disease severity [57, 58], whereas in CTCL
at disease progression chemokine receptors, expressed by
skin-infiltrating T cells and surface molecules, have shown
the tendency to decrease due to loss of these markers
subsequently followed by diminished epidermotropism [59,
60].
However in contrast for chronic AD lesions there is an
increase of Th1 cytokines: interferon-𝛾, IL-12, IL-5, and GM-
CSF [61, 62]. Recently, it has been suggested that in Th2
cell mediated dermatitis persistence of chronic inflammation
might be induced by TLR2 ligands through IL-4-mediated
suppression of IL-10 [63].
4.1.3. Factors Contributing to Impaired Cellular Immunity
in CTCL. In addition, many other mechanisms might be
responsible for the inhibition of cellular immunity by
CTCL such as dysregulated expression of the immunoreg-
ulatory proteins (e.g., CTLA-4, PD-L1 (programmed-death-
ligand 1), and Fas ligand (Fas L)) and constitutive acti-
vation of Jak/Stat pathway, which promotes transforming
growth factor 𝛽 (TGF-𝛽) and IL-10 secretion [43, 64–66].
Programmed-death-receptor-1 (PD-1), amembranemolecule
of CD28/CTLA-1 receptor family, plays an important role in
cellular immunity. By interaction with its ligands it has been
shown to inhibit T cell activation and proliferation [67]. It
has been demonstrated to be highly expressed by neoplastic
T cells in SS [68]. Although its role in pathogenesis of CTCL
is not clear, it might contribute to the immunosuppression in
SS [68, 69].
Defective apoptosis has been shown to be characteristic of
SS. It has been demonstrated to correlate with decreased or
impaired death receptor mainly Fas expression by neoplastic
T cells, resulting in perpetual neoplastic T cell proliferation
[70–75].
Further it has been shown that adhesion molecules and
chemokines have a significant contribution to skin-homing
of malignant T cells in CTCL. The mechanisms are not
yet fully elucidated, but some factors that promote T cells
prone to skin-homing, for example, adhesion molecules
and chemokines, have been identified. Among them are
cutaneous lymphocyte-associated antigen (CLA), chemokine
receptor 4 (CCR4), CCR10, and CCR7 whose expression has
been demonstrated by malignant T cells in patients with MF
and SS [76–82]. CXCR4, a receptor for CXCL12, which can
also be observed in SS,may contribute to cell skin recruitment
and accumulation through the regulatory activity of CD26 in
CTCL [83, 84]. The mechanisms are not yet fully elucidated,
but some factors that promote T cells prone to skin-homing,
for example, adhesion molecules and chemokines, have been
identified [77, 82, 83, 85].
4.1.4. Aspects Leading to Impaired Skin Barrier in AD. The
major hallmarks in the pathogenesis of AD are an impaired
epidermal skin barrier function and an immune dysregula-
tion. Genetic background with filaggrin protein gene muta-
tions alongwith other factors such as skin cytokine imbalance
leads to decreased filaggrin expression, which belongs to one
of the most crucial factors underlying the epidermal barrier
dysfunction in AD [10, 31]. Moreover, filaggrin deficiency
has been associated with subclinical inflammation, reduced
resistance to irritants and haptens, and an enhanced percu-
taneous allergen sensitizing [10]. Another peculiarity in AD
is decrease and alterations in lipids such as ceramides of the
stratum corneum. Besides keratinocytes not only maintain
the first line of physical barrier but also express pattern
recognition receptors for several agents including proteolytic
allergens that are also capable of inducing Th2 cell mediated
immune responses [10].
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Several host and environmental aspects contribute to
the epidermal barrier dysfunction in AD that increase skin
penetration for allergens, microorganisms, and irritants.
4.2. Joint Aspects of Pathogenesis of SS (L-CTCL) and AD
4.2.1. Th2 Weighted Immune Response. Although in early
stages of MF a dominance of Th1 immune answer is pre-
vailing, a later progression of the disease reveals an immune
response that is dominated by Th2 malignant T cells. Th2
weighed immune response is characteristic of an acute phase
of atopic dermatitis as well [18, 30, 33, 44].
In SS, a Th2 weighed immune response is present with
an overproduction of the typical cytokine profile, IL-4, IL-5,
IL-10, and IL-13, respectively, and additionally elevated levels
of serum immunoglobulin E (IgE) and immunoglobulin A
(IgA) and peripheral eosinophilia [33, 42, 44, 86]. Along
with the disease progression, a decline in the number and
activity of benign immune cells results in an impaired cell
mediated cytotoxicity and decreased antigen-specific T cell
responses and consecutively in a severe immunodeficiency
[17, 33]. Interestingly, in SS patients a global Th2 bias with
enhanced production of Th2 cytokines has been shown to
be characteristic of both benign and malignant T cells. Th2
bias was demonstrated to be intrinsic in malignant T cells but
extrinsic in benign T cells. It has been demonstrated that the
Th2 cytokines from malignant cells are capable of inhibiting
theTh1 responses [33].
Atopic Dermatitis Is Also Th2 Prototypic Disease in the
Acute Phase. Consequently, in the acute phase a predomi-
nance of Th2 cytokines, IL-4, IL-5, and IL-13, is observed;
therefore with regard to cytokine profile some parallels
between AD and L-CTCL can be drawn.
This Th2 phenotype shift may be an important factor
prompting an infectious susceptibility observed in patients
with SS as well as AD [14, 75, 76]. A better understanding
of these interactions in SS and AD would promote further
targets for treatment.
4.2.2. Overlapping Factors That May Promote Th2 Weighed
Immune Response in Both AD and SS. Eotaxins, chemokine
ligands (CCL) CCL11 and CCL26 that are expressed by
epidermal keratinocytes and dermal fibroblasts support the
chemotaxis of Th2 cells positive for chemokine receptor 3
(CCR3) and eosinophils, thereby also promoting theTh2 bias
[39, 87–90]. There is an increased expression of CCL11 and
CCL26 both in serum and in lesional skin in AD patients
therefore suggesting that it might also play an important role
in the pathogenesis of the disease [91, 92]. Also in patients
with advanced MF/SS elevated CCL11 and CCL26 levels in
comparisonwith healthy individuals have been demonstrated
[90].
In addition, elevated serum levels of TSLP that activates
immature myeloid dendritic cells (DC) to produce CCL17 in
CTCL patients were detected. Also in AD high expression
in keratinocytes in affected skin lesions was seen and TSLP
might promote leading towards a Th2 phenotypic immune
response [55, 93–95].
4.3. Joint Aspects of Pruritus in AD and SS (L-CTCL).
Several receptors, secreted molecules (histamine, nerve
growth factor (NGF), and substance P (SP)), proteases,
and cytokines/chemokines (thymic stromal lymphopoietin
(TSLP), IL-2, IL-4, IL-13, and IL-31) along with many oth-
ers are described as contributing to chronic pruritus [96].
Although the role of distinct players in AD is ambiguous,
IL-31 strongly contributes to pruritus in AD also correlating
with the severity of the disease [97, 98]. Interestingly, some
studies have suggested that there is no general relation-
ship between IL-31 protein expression and pruritus in Th2
weighted diseases. Therefore, IL-31 might play a distinct role
in the pathogenesis of AD [17].
Although tumor cells in MF/SS exhibit similar cytokine
profile with AD and both are characterized with pruritus,
the analysis of the IL-31 pathway inMF/SS patients regarding
serum levels as well as receptor expression does not suggest
a central role of IL-31 in MF/SS pathogenesis. Nevertheless
increased levels of IL-31 were observed in patients with severe
pruritus; therefore it might be a rationale for therapeutic
approach for some patients [99].
4.4. Joint Factors of Immune Dysregulation Leading to
Increased Infectious Susceptibility in SS and AD. Regarding
atopic dermatitis it is still a matter of debate whether the
primary factor is the disturbed immune response that results
with a defective epidermal skin barrier function or vice versa.
Nevertheless, there is no doubt that both components have
a strong contribution and there is a close interaction among
them; moreover once the inflammatory cascade has been
activated they both belong to the Circulus vitiosus.
Keeping in mind that acute AD and L-CTCL are both
characterized by Th2 phenotypic immune response one
would expect some overlap in clinical consequences as well.
In both AD and L-CTCL Th2 cytokines modulate the
immune response and lead to defective cutaneous barrier
function by impairing keratinocyte protein differentiation
and downregulating the antimicrobial peptides in the skin
and therefore the innate immunity of the skin. Both the
immune dysregulation and the decreased skin barrier predis-
pose to an extensive bacterial colonization and increased risk
of skin infections, which can be observed in patients with AD
and SS as well [100–102].
Whereas for both AD and L-CTCL the immune dysregu-
lation promotes the increased susceptibility to infections, in
case of L-CTCL this aspect appears to play the major role.
As already mentioned above, there is reduced skin
microbiome diversity among AD patients with a prevailing
colonization of Staphylococcus aureus (S. aureus). In patients
withMF and SS, there likewise seems to be an overabundance
of staphylococcal carriage to a similar extent as in AD [16,
103–105].
Besides IgE antibodies against S. aureus toxins have been
shown to exhibit superantigen properties, which appear to
correlate with the severity of the disease [106]. In addition,
S. aureus toxins themselves exhibit superantigen properties
[107]. Moreover, it has been shown that staphylococcal
enterotoxin B (SEB) upregulates IL-31 in peripheral blood
mononuclear cells [108, 109]. It is assumed that signal
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transducer and activator of transcription 3 (Stat3) and the
immunoregulatory cytokine interleukin 10 (IL-10) may play
an important role in immune dysregulation in CTCL. During
disease progression malignant activation of Stat3 and expres-
sion of IL-10 increase in parallel with the evolving immune
impairment [42, 65, 110, 111].
Furthermore, it has been shown recently that microbial
toxins, namely, staphylococcal enterotoxins, might be part of
vicious circle not only as an epiphenomenon but also by stim-
ulating benign T cells to induce activation of the immunoreg-
ulatory Stat3/IL-10 axis in malignant T cells. Accordingly in
CTCL colonization with S. aureus that produces enterotoxin
may promote the skin immune dysregulation [112].
Eradication of pathogen skin microflora has been asso-
ciated with clinical improvement by several authors [16, 104,
112, 113].
Furthermore, therapies that inhibit Th2 cytokine activ-
ity, hence keeping a balance of Th1 responses, may have
the potential to enhance both antipathogen and antitumor
responses [16, 33, 114, 115].
5. Therapy
In both SS and AD there is a repertoire of standard therapies
that is used according to current guidelines in respect of
the extent of skin and systemic involvement [116–119]. These
standards will not be discussed in this review. In the past
years newly developed therapeutic agents have led to a
dramatically improved therapeutic outcome and change of
treatment rationale for many diseases. This is particularly
true for cancer therapy and in dermatology revolutionizing
the treatment for melanoma implementing targeted therapy.
The aim of targeted therapy is the destruction of tumor
cells and induction of as few side effects as possible. Due
to the complexity of cancer and having no exclusive target
markers on cancer cells this concept comes not always
true but nonetheless has led to an immense advancement
and better understanding of the pathophysiology in many
diseases. Targeted therapies have been developed not only
for cancer but also for inflammatory diseases. Despite the
efforts in developing effective treatments inCTCLuntil today,
apart from stem cell transplantation cure is not achievable
[120]. However, induction of partial or complete remission is
possible [121].
In the following, we focus on immunologic checkpoints
that are of interest in SS and are currently implemented in
clinical studies. We compare the checkpoints to data drawn
from studies in AD and/or evaluate potential benefits from
transferring therapeutic approaches from one entity to the
other. The list of targets mentioned here is not exhaustive.
All information about ongoing studies without published
results was obtained at the official homepage of the registry
and results database for clinical studies in human par-
ticipants: https://clinicaltrials.gov/. An overview about the
targets discussed in this review is given in Table 1. Detailed
information and references are to be found in the text.
5.1. Targeting Structures of the Immune System. SS arises from
the lymphocytic system, which is per se part of the immune
system. The cell of origin is a central memory T cell with
the ability of circulation in skin, blood, and lymph nodes [1].
Therefore, targeted therapy for SS always means interacting
with immune mechanisms.
In AD multiple factors seem to contribute to this con-
dition such as underlying genetic predisposition and envi-
ronmental factors. Excessive T cell activation is characteristic
of AD with still unclear exact pathophysiologic mechanisms
[122]. Targeting the T cells and/or the environment of
neoplasm/inflammation is a reasonable approach in both dis-
eases. The aim-result of targeted therapy is either induction
of immunotoxic effects on cancer cells or modification of
immunological mechanisms. The latter is the more common
in the currently developed agents. In malignant T cell prolif-
eration blocking immunosuppression or enhancing the local
immune response is supposed to be beneficial. Many targets
to act on these differing approaches are under exploration.
5.2. Targets on T Cells. Alemtuzumab is a humanized mon-
oclonal anti-CD52 directed antibody. CD52 is described as a
pan-T- and B-cell-marker, expressed also on dendritic cells
and macrophages. Alemtuzumab has proven to be especially
useful in SS andMFwith leukemic involvement, which seems
to be related to the cell of origin of the clonal malignancy and
its surface marker profile [1, 123]. It leads to a depletion of
circulating lymphocytes and thereby suppression of immune
responses [124]. Application may result in severe adverse
events, mainly infections [125]. Its use in AD has to be
discussed carefully. There is no data published on this topic.
Ipilimumab (Yervoy) is a monoclonal antibody targeted
against CTLA-4. CTLA-4 obviously is overexpressed in
CTCL and SS and coincides in the latter with abnormal
findings for IL-10 and Foxp3 [126]. This phenotype would
suggest a differentiation towards Tregs [41]. Blocking CTLA-
4 might therefore be an interesting therapeutic approach.
However, there is no data yet on CTLA-4 inhibition in
CTCL and the exact mechanism of action has not yet been
completely elucidated. Overexpression of CTLA-4 in CTCL
could be interpreted as feature either of an immune escape
mechanism or potentially of immunosuppression [127]. In
Hodgkin lymphoma a study for exploration of the combina-
tional therapy of ipilimumab with brentuximab vedotin and
nivolumab has been initiated. The three agents are used in
three different arms comparing nivolumab + brentuximab
vedotin versus ipilimumab + brentuximab vedotin versus the
combination of all the three drugs. Transferring the results
of this study will be highly interesting for the treatment of
CTCL, especially CTCL with CD30 expression.
PD-1 and programmed-death-ligand 1 (PD-L1) are
immunologic checkpoints on T cells and cancer cells,
respectively, and their therapeutic blockage has led to
convincing results for overall survival improvement in non-
small-cell lung cancer, melanoma, and other solid tumors
[128]. Approved inmelanoma and non-small-cell lung cancer
in Europe are two PD-1-inhibitors pembrolizumab (MK-
3475/Keytruda) and nivolumab (Opdivo). A phase 2 study
with pembrolizumab for the treatment of relapsed/refractory
MF/SS is active. Estimated primary completion date is
January 2018. PD-L1-inhibitors are not yet approved but
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being tested in solid tumors and systemic lymphoma.
Though not yet studied in CTCL, they probably will be in
near future.
CCR4 is the receptor for CCL17 and CCL22 and is
expressed mainly on CD4+ T cells with Th2 polarization. It
can also be detected on other cells of the immune system like
macrophages and dendritic and NK cells [129]. In SS CCR4
expression could be observed in the peripheral blood and in
the skin [77].
Mogamulizumab (Poteligeo) (Anti-CC chemokine recep-
tor 4 (CCR4)) is a new humanized monoclonal antibody
obtainable in clinical studies for use in CTCL and SS and
is currently in a phase 3 study in comparison with the
HDAC inhibitor vorinostat (Zolinza). In a phase 1/2 study
in patients with CTCL, the subgroup of 19 SS patients
showed the highest overall response rates with 47.1% [130].
Mogamulizumab leads to a depletion of CCR4+ malignant T
cells and CCR4+Tregs. This mechanism is of great potential
in T cell lymphoma therapy [131]. As mentioned above T
cells are CCR4+ in both AD and SS [132]. Whether the
depletion of Tregs via the CCR4 receptor might be beneficial
in atopic patients has yet to be shown. A phase 1 trial has been
conducted in patients with asthma. The results are still being
evaluated.
5.3. Immunologic Targets in the Environment. Interleukin 12
(IL-12) is a promising target in CTCL and inflammatory
skin diseases. In pediatric AD patients IL-12 levels in serum
have been reported to be high [133]. Interestingly, the IFN
serum levels, which would be expected to increase by
stimulation through IL-12, are comparably low, leading to
the assumption that the normal IL-12/IFN pathway is not
intact [134]. Reduced IL-12R beta (2) mRNA expression
may be the cause of low IL-12 receptor expression. High
IL-12 without a binding receptor would have no cellular
effects and would explain the low IFN serum levels [135].
IL-12 substitution would in this case not be beneficial for
AD patients. In CTCL induction of lesion regression and
cytotoxic T cell responses have been described under IL-12-
therapy [136]. A phase 2 study with NM-IL-12 (recombinant
human IL-12) should start in November 2015 as a single arm,
open-label, nonrandomized studywithNM-IL-12 (150 ng/kg)
dosed in combination with low dose total skin electron beam
(TSEB) in CTCL patients including patients with SS. IL-12
in this setting acts as immunotherapy to increase antitumor
efficacy against CTCL, supposedly reducing skin-related
toxicity.
IL-13 has just recently been described as a contributor
to growth of tumor cells in CTCL. IL-4 and IL-13 seem to
act synergistically in this setting [137, 138]. Based on this
detection, blockage of IL-13 receptor might be beneficial. An
IL-13-R-inhibitor is available in experimental studies under
the name lebrikizumab (TNX-650). The drug has been used
in a phase I study in Hodgkin’s lymphoma and is currently
under investigation in a phase 2 study inAD. Results for these
two studies are not yet published. For asthmatic patients the
application of lebrikizumab showed improvement and was
considered as safe and of good tolerability [139]. Another IL-
13-R-inhibitor that is in use in clinical studies is tralokinumab.
As mentioned above the synergism between IL-4 and IL-
13 seems to contribute to tumor cell growth. With regard to
this, targeting IL-4 or IL-4-receptor, respectively, would be
another therapeutic option. A human monoclonal antibody
against the IL-4-receptor (IL4R), dupilumab, revolutionizes
the therapy in AD [140–142]. It is directed against the shared
alpha subunit of the IL4R and, by IL4R blockage, it modulates
signaling of both the IL-4 and IL-13 pathway. Exploration of
IL-4 in SS showed a significant elevation of IL-4 positive cells
compared to inflammatory dermatoses [143]. This finding
would support the rationale for treating CTCL patients,
especially SS patients, with IL-13/IL-4 inhibitors.
Resimmune (or A-dmDT390-bisFv(UCHT1) Immuno-
toxin) (Angimmune LLC) is a recombinant immunotoxin
selectively targeting the CD3 receptor and temporarily
depleting all T cells. It has been shown that sensitivity of
malignant T cells to this drug is 30 times higher compared to
normal resting T cells. The drug may have an immunomod-
ulatory effect by activating novel naive T cells contributing
to further deletion of residual tumor cells [144]. Resimmune
has been investigated in a clinical phase 2 study in patients
with CTCL, including patients with SS. The results are not
yet published.
Ten different types of toll-like-receptors (TLR) have been
described in human until today. Their localization on
antigen-presenting plasmacytoid and myeloid dendritic cells
and their role in the immune response in cancer render them
attractive targets for treatment. Apoptosis of tumor cells (e.g.,
under radiotherapy) and treatmentwithTLRmay lead to syn-
ergistic effects [145, 146]. TLR7 agonist (imiquimod/Aldara)
is available for topical application and is approved in Europe
for treatment of superficial basal cell carcinoma and actinic
keratoses. Its effects have also been shown for CTCL patients
with response rates up to 50% [147–149]. TLR9 agonist (CPG
7909) has been applied subcutaneously to SS and MF in
a phase I study enrolling 28 patients. Clinical response
rate was 32% [150]. In another study, TLR9 agonist was
injected intralesionally and combined with radiation in 14
MF patients leading to the immunological effect of an in
situ vaccination. The overall response rate was 35.7% [151].
In mouse the TLR9 agonist was combined with ibrutinib,
which is a Bruton-tyrosine kinase-inhibitor. This approach
led to an enhancement of the antitumor response [152].
This effect of the combination will have to be evaluated
in humans and maybe become a therapy option in the
future.
Anti-CXCR4 is a potential treatment option for patients
with SS. Because of CXCR4 overexpression in SS and MF,
clinical studies for this target would be interesting [84].
For systemic lymphoproliferative diseases like acute myeloid
leukemia the antibody plerixafor (Mozobil) is in use.Though
there is not yet a study running in CTCL, exploration of this
therapy in near future is very likely.
IL-22 is produced by T cells. Primarily its role in inflam-
mation in human skin has been in focus, for example, in
AD, but obviously it is also involved in the pathogenesis
of malignant skin proliferation [153]. In CTCL elevated
levels of mRNA and protein levels were detected for IL-
22 [154]. Fezakinumab (ILV-094), a monoclonal antibody
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against IL-22, is being investigated in a phase 2 study in AD.
Experimental use in CTCL could give interesting results.
Another interleukin that could be important in signaling
in CTCL is IL-18. IL-18 has been interrelated to linking
inflammatory immune responses and tumor progression
[155]. In skin lesions increased IL-18 expression has been
detected and potentially contributing to the elevation to
serum levels in patients with CTCL and cutaneous NK cell
lymphoma [156, 157].High levels of IL-18 have been described
in other skin malignancies as well. This might therefore be
either a sharedmechanism in skin tumorigenesis or part of an
immune response mechanism [158]. Assuming that high lev-
els of IL-18 are beneficial in cancer or lymphoma, respectively,
human recombinant IL-18 (SB-485232) was administered in
combination with rituximab in a phase 1 study to patients
with non-Hodgkin’s lymphoma (NHL) revealing a response
rate of 26% [159]. Phase 2 studies inNHLare ongoing. Further
workup is needed in patients with SS to clarify the role of
IL-18 and to be able to evaluate if patients would profit from
this treatment. In AD serum levels for IL-18 are found to be
elevated likewise [160, 161]. Whether IL-18 application would
be valuable for the patient is discussed controversially. Some
authors propose that IL-18 might trigger the development of
skin lesions in AD [162].
5.4. Others. In addition to all of the above-mentioned treat-
ments in CTCL, there are many more that may have, not
directly but indirectly, effects on the immune response. Epi-
genetic modifiers like histone deacetylase (HDAC) inhibitors
or substances that interact with JAK/Stat or NF𝜅B may
have influence on disease evolution. Furthermore, there
are proteasome inhibitors like bortezomib (VELCADE)
that have been used in SS and targeted therapy directed
against molecules expressed on cancer cells and linked to
cytotoxic agents like the already well-established anti-CD30
antibody-drug conjugate brentuximab vedotin (Adcetris)
[163]. Expression of CD30 is not exclusively restricted to
cancer cells, though there are only few cell types in a healthy
individual with CD30 surface markers [164]. Tyrosine kinase
inhibitors like dasatinib have been developed. B-lymphoid
tyrosine kinase is a designated oncogene that could be
targeted by dasatinib in CTCL [165]. A study has been
conducted in metastatic and/or not surgically removable
lesions in various types of lymphoma, including CTCL and
SS. Results have not yet been published.
6. Conclusion
Overlapping features in immune responses in both diseases
might be used for transferring knowledge for targetmolecules
from one entity to the other.
A better understanding of the underlying mechanisms
and new markers will hopefully yield further improvement
of targeted treatment options in both AD and SS. Several
promising diagnostic and clinicalmarkers and new treatment
options targeting checkpoints in the immune system have
already been discovered and are implemented in clinical
studies both for SS and for AD. In SS, there is still a need
for efficacious therapy. Blocking the immunosuppressive
mechanisms orchestrated by malignant T cells as well as
enhancing the local immune response could be beneficial.
Further exploration is necessary to prolong the life of patients
and improve their quality of life.
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